AELIS FARMA SAS (AELIS.PA) Stock Price, Quote, News and Overview
EPA:AELIS - Euronext Paris - Matif - FR0014007ZB4 - Common Stock - Currency: EUR
AELIS.PA Quote, Performance and Key Statistics
EPA:AELIS (6/17/2025, 7:00:00 PM)
1.16
0 (0%)
The current stock price of AELIS.PA is 1.16 EUR. In the past month the price decreased by -7.94%. In the past year, price decreased by -90.94%.
AELIS.PA Competitors/Peers
Symbol | Company Name | TA | FA | PE | Market Cap |
|---|---|---|---|---|---|
| 1ABBV.MI | ABBVIE INC | 18.69 | 293.65B | ||
| 4AB.DE | ABBVIE INC | 18.09 | 283.68B | ||
| AMG.DE | AMGEN INC | 14.23 | 137.38B | ||
| GIS.DE | GILEAD SCIENCES INC | 14.11 | 117.44B | ||
| VX1.DE | VERTEX PHARMACEUTICALS INC | N/A | 99.51B | ||
| 1REGN.MI | REGENERON PHARMACEUTICALS | 11.98 | 49.56B | ||
| ARGX.BR | ARGENX SE | 102.34 | 28.87B | ||
| 22UA.DE | BIONTECH SE-ADR | N/A | 21.80B | ||
| IDP.DE | BIOGEN INC | 8.15 | 16.35B | ||
| 1EXEL.MI | EXELIXIS INC | 18.93 | 9.81B | ||
| 1MRNA.MI | MODERNA INC | N/A | 8.71B | ||
| 0QF.DE | MODERNA INC | N/A | 8.67B |
Related stock screener links
About AELIS.PA
Company Profile
Aelis Farma SA is a biopharmaceutical company. The company is headquartered in Bordeaux, Nouvelle-Aquitaine. The company went IPO on 2022-02-18. The firm provides two products in clinical development, including AEF0117 for cannabis-related disorders (severe dependence, acute psychosis, and acute toxicity), and AEF0217 for cognitive deficits (disorders related to Down syndrome). The company offers viable treatments for certain pathological conditions linked to hyperactivity of the CB1 receptor, the main receptor of the endocannabinoid system. The company provides advanced drug AEF0117, to combat the harmful effects of cannabis and in particular Cannabis Use Disorders (CUD) which is the current definition of cannabis addiction in the diagnostic manual reference DSM-5. The firm operates a Research and Development (R&D) platform, which enables the Company to discover drug candidates that act as specific modulators of target receptor signaling.
Company Info
AELIS FARMA SAS
Neurocentre Francois Magendie 146 Rue Leo, Saignat
Bordeaux NOUVELLE-AQUITAINE FR
Employees: 26
Phone: 33557573770
AELIS FARMA SAS / AELIS.PA FAQ
What is the stock price of AELIS FARMA SAS today?
The current stock price of AELIS.PA is 1.16 EUR.
What is the ticker symbol for AELIS FARMA SAS stock?
The exchange symbol of AELIS FARMA SAS is AELIS and it is listed on the Euronext Paris - Matif exchange.
On which exchange is AELIS.PA stock listed?
AELIS.PA stock is listed on the Euronext Paris - Matif exchange.
What is the price forecast or stock price prediction for AELIS FARMA SAS stock?
10 analysts have analysed AELIS.PA and the average price target is 7.65 EUR. This implies a price increase of 559.48% is expected in the next year compared to the current price of 1.16. Check the AELIS FARMA SAS stock analysts ratings, price target forecast and up-and down grades for more detailed information.
What is AELIS FARMA SAS worth?
AELIS FARMA SAS (AELIS.PA) has a market capitalization of 15.90M EUR. This makes AELIS.PA a Nano Cap stock.
How many employees does AELIS FARMA SAS have?
AELIS FARMA SAS (AELIS.PA) currently has 26 employees.
What are the support and resistance levels for AELIS FARMA SAS (AELIS.PA) stock?
AELIS FARMA SAS (AELIS.PA) has a support level at 1.16 and a resistance level at 1.31. Check the full technical report for a detailed analysis of AELIS.PA support and resistance levels.
Is AELIS FARMA SAS (AELIS.PA) expected to grow?
The Revenue of AELIS FARMA SAS (AELIS.PA) is expected to decline by -52.86% in the next year. Check the estimates tab for more information on the AELIS.PA EPS, Sales, EBIT and EBITDA future analyst estimates.
Should I buy AELIS FARMA SAS (AELIS.PA) stock?
There is no straightforward answer here. It depends on your investment strategy as different types of investors will look at different aspects. In any case it is important to make an informed decision and these pages can help you forming an opinion:
- The Technical Analysis (TA) tab contains a technical analysis of AELIS.PA, looking at technical quality and support and resistance levels
- The Fundamental Analysis (FA) tab contains a fundamental analysis of AELIS.PA, evaluating the profitability, health, valuation and growth aspects
- AELIS FARMA SAS (AELIS.PA) Price Target Forecast and Analysts Ratings to understand what professional analysts say.
- AELIS FARMA SAS (AELIS.PA) Sales and EPS estimates to see what analysts future expectations are.
- AELIS FARMA SAS (AELIS.PA) Income, Balance Sheet and Cash Flow statements to dive into the historical financials.
- AELIS FARMA SAS (AELIS.PA) Insider and Institutional Ownership to learn about the owners and their transactions.
- AELIS FARMA SAS (AELIS.PA) Stock Chart to make your own analysis
- AELIS FARMA SAS (AELIS.PA) Latest news and press-releases to stay up to date.
Does AELIS FARMA SAS (AELIS.PA) stock pay dividends?
AELIS.PA does not pay a dividend.
What is the Price/Earnings (PE) ratio of AELIS FARMA SAS (AELIS.PA)?
AELIS FARMA SAS (AELIS.PA) does not have a PE ratio as the earnings reported over the last twelve months were negative (-0.55).
AELIS.PA Technical Analysis
AELIS.PA Fundamental Analysis
ChartMill assigns a fundamental rating of 2 / 10 to AELIS.PA. While AELIS.PA seems to be doing ok healthwise, there are quite some concerns on its profitability.
AELIS.PA Financial Highlights
Over the last trailing twelve months AELIS.PA reported a non-GAAP Earnings per Share(EPS) of -0.55. The EPS decreased by -41.87% compared to the year before.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PM (TTM) | N/A | ||
| ROA | -37.83% | ||
| ROE | -73.69% | ||
| Debt/Equity | 0.39 |
AELIS.PA Ownership and Analysts
ChartMill assigns a Buy % Consensus number of 82% to AELIS.PA. The Buy consensus is the average rating of analysts ratings from 10 analysts.
For the next year, analysts expect an EPS growth of -34.44% and a revenue growth -52.86% for AELIS.PA